CalciMedica, Inc. (CALC) Stock Price & Analysis
CalciMedica, Inc. (CALC) closed at USD 1.08 on Thursday, October 15, 2026, up 0.93% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.07; the Oct 15, 2026 session ranged USD 1.05–1.15 on volume of 22,476 shares. Market capitalization is $7.37M, with a 52-week range of USD 1.03–36 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:10 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CALC.md
Key facts (CALC)
- Analysts: Buy (mean 2.25 on a 1–5 scale) (4 analysts), mean target USD 50 (range 30–75).
- Total return with dividends: 1Y -93.3% vs S&P 500 +18.1%; 5Y -95.7% vs S&P 500 +85.1%.
Analysts (CALC)
Consensus Buy (mean 2.25 on a 1–5 scale), 4 analysts; mean target USD 50 (low 30, high 75).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-20 | Guggenheim | Initiated | Buy | $9 |
Total return (dividends reinvested) (CALC)
| 1Y (from 2025-10-16) | 5Y (from 2023-06-12) | |
|---|---|---|
| Total return | -93.3% | -95.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -93.4% | -61.0% |
| Volatility (annualized) | 186.1% | 139.5% |
| Max drawdown | -96.8% (Jan 2026→Oct 2026) | -96.8% (Dec 2025→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:10 UTC)
| Price | USD 1.08 |
|---|---|
| Change | ▲ 0.93% (up) |
| Previous Close | USD 1.07 |
| Open | USD 1.08 |
| Day Range | USD 1.05 – 1.15 |
| 52-Week Range | USD 1.03 – 36 |
| Volume | 22,476 shares |
| Market Cap | $7.37M |
| Exchange | NCM |
Technical Analysis (CALC)
Nexqual's technical model rates CALC "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:10 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 17.34 (oversold) |
| vs SMA50 | Below (USD 2.19) |
| MACD | -0.31 (negative) |
Analyst Ratings (CALC)
Wall Street analysts rate CALC "Buy" based on 4 analysts, with a mean price target of USD 50 (range USD 30–75), per Nexqual as of October 16, 2026 at 05:10 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 50 |
| High Target | USD 75 |
| Low Target | USD 30 |
| Buy / Hold / Sell | 3 / 1 / 0 |
Earnings (CALC)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -2.25 vs est -1.45 ▼ miss |
| 2026-03-31 | USD 1.5 vs est -1.4 ▲ beat |
| 2025-12-31 | USD -3.45 vs est -2.06 ▼ miss |
| 2025-09-30 | USD -2.6 vs est -2.06 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:10 UTC.
Financials & Fundamentals (CALC)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -365.70% |
| Debt / Equity | 1.67 |
| Current Ratio | 5.58 |
| Total Cash | $18.62M |
| Total Debt | $9.20M |
Source: Nexqual, October 16, 2026 at 05:10 UTC.
Financial Health Score (CALC)
Nexqual rates CalciMedica, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:10 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Weak — $19M cash vs $9M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$19M (TTM) |
| Efficiency | Critical — ROE -366%, ROA -63.6% |
Ownership (CALC)
| Insider Ownership | +18.53% |
|---|---|
| Institutional Ownership | +57.51% |
| Shares Outstanding | 6.83M |
| Float | 3.79M |
| Short % of Float | +2.28% |
Source: Nexqual, October 16, 2026 at 05:10 UTC.
Leadership (CALC)
CalciMedica, Inc. is led by A. Rachel Leheny (age 62), CEO & Director, per Nexqual as of October 16, 2026 at 05:10 UTC.
| CEO & Director | A. Rachel Leheny (age 62) |
|---|---|
| Chief Business Officer & Vice Chairman of the Board | Eric W. Roberts (age 61) |
| President & COO | Michael J. Dunn B.A. (age 69) |
| Co-Founder & Chief Scientific Officer | Kenneth A. Stauderman (age 71) |
| Chief Financial Officer | Stephen B. Bardin (age 34) |
Major Backers & Investors (CALC)
Notable institutional backers of CalciMedica, Inc. include Woodline Partners LP, Heights Capital Management, Inc , Squadron Capital Management LLC, according to Nexqual as of October 16, 2026 at 05:10 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Woodline Partners LP | 7.29% |
| Heights Capital Management, Inc | 4.56% |
| Squadron Capital Management LLC | 3.65% |
| Stempoint Capital LP | 3.65% |
| Stonepine Capital Management, LLC | 1.82% |
| L1 Global Manager Pty Ltd | 0.73% |
| Morgan Stanley | 0.42% |
| Fidelity | 0.31% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.52% |
| Geode Capital | 0.32% |
Source: Nexqual, October 16, 2026 at 05:10 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:10 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt